A monoclonal antibody against prostate stem cell antigen (PSCA) has emerged as a novel cancer therapy currently being tested in clinical trials for prostate and pancreatic cancers, but this treatment is likely to be efficient only in patients with PSCA-expressing tumors. The present study demonstrates that a genetic variant (rs2294008) discovered by bladder cancer genome-wide association studies is a strong predictor of PSCA protein expression in bladder tumors, as measured by two-sided multivariable linear regression (P = 6.46×10-11; n = 278). The association pattern is similar in non-muscle-invasive tumors, stages Ta (P = 3.10×10-5; n = 173) and T1 (P = 2.64×10-5; n = 60), and muscle-invasive tumors, stages T2 (P =.01; n = 23) and T3/4 (P =.03; n = 22). The study suggests that anti-PSCA immunotherapy might be beneficial for bladder cancer patients with high tumor PSCA expression, which is statistically significantly associated with the presence of CT and TT genotypes of a common genetic variant, rs2294008. Future clinical studies will be needed to validate PSCA as a therapeutic target for bladder cancer. © 2012 The Author.
CITATION STYLE
Kohaar, I., Porter-Gill, P., Lenz, P., Fu, Y. P., Mumy, A., Tang, W., … Prokunina-Olsson, L. (2013). Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer. Journal of the National Cancer Institute, 105(1), 69–73. https://doi.org/10.1093/jnci/djs458
Mendeley helps you to discover research relevant for your work.